¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀå : ºÐÀÚ À¯Çüº°, Åõ¿© °æ·Îº°, Ä¡·á ¿µ¿ªº°, ¾àÁ¦ Ŭ·¡½ºº°, À¯Åë ä³Îº°, Áö¿ªº°
Injectable Drugs Market, By Molecule Type, By Route of Administration, By Therapeutic Area, By Drug Class, By Distribution Channel, By Geography
»óǰÄÚµå : 1705690
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,315,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,823,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,034,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀåÀº 2025³â 6,140¾ï 7,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â±îÁö 1Á¶ 327¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ ¼ºÀå·ü(CAGR) 7.7%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 6,140¾ï 7,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£: 2025-2032³â CAGR: 7.70% 2032³â °¡Ä¡ ¿¹Ãø 1Á¶327¾ï 8,000¸¸ ´Þ·¯
±×¸². ÁÖ»çÁ¦ ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
Injectable Drugs Market-IMG1

ÁÖ»çÁ¦´Â ÁÖ·Î Á¤¸Æ, ±ÙÀ°, Á¶Á÷À» ÅëÇØ ½Åü¿¡ Á÷Á¢ Åõ¿©µÇ´Â ¾à¹°À» ¸»ÇÕ´Ï´Ù. ¾à¹° Àü´ÞÀº Ç÷·ù·Î Á÷Á¢ ¾à¹°À» Àü´ÞÇÒ ¼ö Àֱ⠶§¹®¿¡ ´Ù¾çÇÑ Áß¿ä Ä¡·á Ä¡·á¿¡¼­ ´Ù¸¥ ¾à¹° Àü´Þ ¹æ¹ýº¸´Ù ¼±È£µË´Ï´Ù. ¾à¹° Àü´Þ ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀǾàǰ Ȱ¼º ¼ººÐÀÇ ¾ÈÁ¤¼º, ¿ëÇØ¼º ¹× »ýüÀÌ¿ë·üÀÌ °³¼±µÈ »õ·Î¿î ÁÖ»ç Á¦Á¦°¡ °³¹ßµÇ¾ú½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, »ý¹°ÇÐÀû Á¦Á¦ ¹× Ç¥Àû ¾à¹° ¿ä¹ý¿¡ ´ëÇÑ °ü½É Áõ°¡, ÀÚ±â Åõ¿© ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼Ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¾Ï, ´ç´¢º´, ÀÚ°¡¸é¿ªÁúȯ µî ¸¸¼ºÁúȯÀÇ À¯º´·ü »ó½ÂÀÌ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. WHO¿¡ µû¸£¸é ¸¸¼ºÁúȯÀº ¼¼°è »ç¸ÁÀÇ 60% ÀÌ»óÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶Ç, ¾ÏÀ̳ª ÀÚ°¡¸é¿ªÁúȯÀÇ Ä¡·á¿¡ »ý¹°Á¦Á¦³ª Ç¥Àû ¾à¹°¿ä¹ýÀÌ ±Þ¼ÓÈ÷ ä¿ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª, ÁÖ»çÁ¦ÀÇ ¿¬±¸°³¹ß ¹× Á¦Á¶¿¡ µå´Â ºñ¿ëÀÌ ³ôÀº °ÍÀº ½ÃÀå °ü°èÀÚ¿¡°Ô À־ °úÁ¦°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ»çÁ¦¸¦ Åõ¿©ÇÏ´Â µ¿¾È ¹Ù´ÃÀ» Âñ¸®´Â ºÎ»ó À§ÇèÀº º¸±ÞÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ ¸¸¼º Áúȯ °ü¸®¸¦ À§ÇÑ ÀÚ°¡Åõ¿© ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é °¡±î¿î ¹Ì·¡¿¡ ¼ºÀå ±âȸ°¡ »ý±æ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È Çà·ÄÀ» ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.

¼¼°è ÁÖ»çÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷¿¡ ´ëÇØ ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

ÁÖ¿ä ±â¾÷À¸·Î´Â Pfizer, Novartis, Sanofi, GlaxoSmithKline, Gilead Sciences, AbbVie µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í °¢ ±â¾÷ÀÇ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° »ó½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

ÁÖ»çÁ¦ ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚ´Â ¼¼°è ÁÖ»çÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀå, ºÐÀÚ À¯Çüº°, 2020-2032³â

Á¦5Àå ¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â

Á¦6Àå ¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀå, Ä¡·á ¿µ¿ªº°, 2020-2032³â

Á¦7Àå ¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â

Á¦8Àå ¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â

Á¦9Àå ¼¼°èÀÇ ÁÖ»çÁ¦ ½ÃÀå, Áö¿ªº°, 2020-2032³â

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ºÐ¼®°¡ Ãßõ

Á¦12Àå Âü°í¹®Çå°ú Á¶»ç¹æ¹ý

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Injectable Drugs Market is estimated to be valued at USD 614.07 Bn in 2025 and is expected to reach USD 1,032.78 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 614.07 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 7.70% 2032 Value Projection: USD 1,032.78 Bn
Figure. Injectable Drugs Market Share (%), By Region 2025
Injectable Drugs Market - IMG1

Injectable drugs refer to medications that are administered directly into the body, mostly through veins, muscles or tissues. These are preferred over other drug delivery methods for various critical care therapies, owing to their ability to deliver medications directly into the bloodstream, ensuring rapid onset of action. Advancements in drug delivery technologies have led to development of novel injectable formulations with improved stability, solubility and bioavailability of active pharmaceutical ingredients. Growing prevalence of chronic diseases, rising focus on biologics and targeted drug therapies, and increasing demand for self-administered injectables can drive the market growth.

Market Dynamics:

Global injectable drugs market growth is driven by rising prevalence of chronic diseases such as cancer, diabetes and autoimmune disorders. According to WHO, chronic diseases are estimated to account for over 60% of global deaths. Rapid adoption of biologics and targeted drug therapies for treatment of cancer and autoimmune diseases can also drive the market growth. However, high costs associated with R&D and manufacturing of injectable products can pose challenges for the market players. Risk of needle-stick injuries while administering injectables can also hamper its adoption. Growing demand for self-administered injectables especially for management of chronic diseases can offer growth opportunities in the near future.

Key features of the study:

This report provides in-depth analysis of the global injectable drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global injectable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Novartis, Sanofi, GlaxoSmithKline, Gilead Sciences and AbbVie

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global injectable drugs market

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Injectable Drugs Market, By Molecule Type, 2020-2032, (USD Bn)

5. Global Injectable Drugs Market, By Route of Administration, 2020-2032, (USD Bn)

6. Global Injectable Drugs Market, By Therapeutic Area, 2020-2032, (USD Bn)

7. Global Injectable Drugs Market, By Drug Class, 2020-2032, (USD Bn)

8. Global Injectable Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)

9. Global Injectable Drugs Market, By Region, 2020 - 2032, (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â